Bristol-Myers Squibb Company (BMY) exhibits 71.1% gross margins and 13.3% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 16.3x enterprise multiple and 4.8% implied options volatility.
Sustained 71.1% gross profitability converts into 17.9% operating margin and 13.3% ROIC, outpacing sector cost of capital.
ROIC: 13.3% // GM: 71.1%YoY revenue trajectory of -0.2% paired with 10.24% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -0.2% // FCF YLD: 10.24%Altman Z-Score of 2.24 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.24 // F-SCORE: 7/9Trading at 17.8x trailing P/E (16.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 17.8x // EV/EBITDA: 16.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $62.48 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 14.6% net margins.
NET MARGIN: 14.6% // D/E: 2.32x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BMY & activate live FRED threshold breach alerts.